FVFIGP
Flagship Ventures Fund IV General Partner Portfolio holdings
AUM
$585M
This Quarter Return
+4.55%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$585M
AUM Growth
–
Cap. Flow
+$585M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Seres Therapeutics
MCRB
|
$368M |
| 2 |
Editas Medicine
EDIT
|
$121M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$87.2M |
| 4 |
TTOO
T2 Biosystems, Inc
TTOO
|
$5.85M |
| 5 |
Carisma Therapeutics
CARM
|
$2.46M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Seres Therapeutics
MCRB
$174M
| $368M | 62.99% |
+12,682,876
| New | +$368M |
|
|
2
Editas Medicine
EDIT
$235M
| $121M | 20.67% |
+4,955,316
| New | +$121M |
|
|
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $87.2M | 14.92% |
+4,806,656
| New | +$87.2M |
|
|
TTOO
4
DELISTED
T2 Biosystems, Inc
TTOO
| $5.85M | 1% |
+741,755
| New | +$5.85M |
|
|
5
Carisma Therapeutics
CARM
$17.7M
| $2.46M | 0.42% |
+1,466,417
| New | +$2.46M |
|